Akèy › Maladi otoim › Illinois
Etid klinik pou Maladi otoim nan Illinois
14 etid pou Maladi otoim ap chèche patisipan nan sit nan Illinois.
Vil nan Illinois
Tèks ofisyèl etid la (Anglè)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Willow Rheumatology Wellness, Willowbrook
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07621809RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Chicago, Department of Medicine: Rheumatology, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
- University of Illinois Hospital & Health Sciences System, Chicago
Ap rekriteFaz 1/2
Laj 35 a 70 · Tout sèks · Mizajou Aug 21, 2026 · NCT06575426RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Northwestern Memorial Hospital, Chicago
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1054, Schaumburg
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- ak 3 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Northwestern University, Chicago
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 30, 2026 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Northwestern University, Chicago
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 29, 2026 · NCT04422912The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
- University of Chicago Medical Center, Chicago
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Mar 4, 2026 · NCT01280825Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.